Pancreatic cancer diagnosis under review

April 23, 2013
Marta Herreros-Villanueva, UPV/EHU researcher and principal author of the review of pancreatic cancer markers. Credit: UPV/EHU

A team of researchers of the UPV/EHU together with researchers from the Hospital Clínico of Barcelona have produced a bibliographical review that summarises the data currently existing on the markers for pancreatic cancer, and have published it in the specialised journal Clinica Chimica Acta.

The study was led by Marta Herreros-Villanueva through a programme that Luis Bujanda is involved in; both of them are members of staff of the Networked Centre for into Hepatic and (CIBERehd) at the Hospital Donostia, and of the UPV/EHU's Biodonostia Institute. It is an important piece of work that arranges all the existing information on the markers for this disease.

Various may develop in the , but what is commonly known as pancreatic cancer is of the pancreas, which is the most common. "90-95% of pancreatic cancers are adenocarcinomas," says Marta Herreros, main author of the work.

Ductal cells in the pancreas form ducts or tubes that transport what is produced by other pancreatic cell types, the . In ductal adenocarcinoma, the cells form many more ducts than normal. This leads to the formation of tumours.

Adenocarcinoma is not among the most frequent cancer types, but it is among those with the highest mortality rate. And the reason for this is clear for the researchers. "The fact that sets pancreatic cancer apart from other types is that by the time it has been detected, it is very late," explains Herreros. "It isn't because the cells of a pancreatic tumour grow more quickly than those of other kinds of tumours but that the techniques we have for spotting it do not allow us to do so at an early stage." The disease is reckoned to take several years to develop, perhaps between five and ten years, but it does not tend to be diagnosed until the final phase.

Complicated diagnosis

There are in fact two big difficulties hampering the : the difficulty in accessing the pancreas and the lack of good markers for the disease.

Firstly, the pancreas is an internal organ which makes it difficult to get at. "With an endoscopy, for example, you can easily access a tumour of the colon; or with a breast tumour you can also access it easily with a mammography and see it. But accessing the pancreas is complicated. That is why by the time it is diagnosed it is usually late; there is no technique for accessing the pancreas directly and seeing what is there," says Herreros.

Secondly, there is no specific, reliable marker that in fact indicates the presence of an adenocarcinoma. Currently, the diagnosis is made thanks to the CA19-9 marker, a glycoprotein present in the bloodstream of many patients with pancreatic cancer. This marker is a standard one worldwide: it is the molecule that doctors are looking for in blood tests designed to detect pancreatic cancer.

"The CA19-9 is the marker established worldwide. Then, on an experimental level there are some of the molecules we have included in our publication, but they are just clinical trials; the patients are not routinely evaluated using these other molecules," says Herreros.

Furthermore, the CA19-9 is not a very good marker, because it is neither specific nor sensitive. "It isn't very useful in pancreatic cancer because there are patients who, despite having the disease, do not have a very high presence of it, they just have it within very normal ranges, and then there are patients with a high level of this protein who do not have . They may have pancreatitis or other kinds of tumours," explains Herreros.

This means that the prognosis is imprecise and the diagnosis through the analysis of the CA19-9 marker comes too late in many cases.

That is why it is crucial to seek other markers to make a diagnosis . "That's what we're working on," says Herreros. "But it's very complicated and there aren't many samples or many patients to analyse, because of the high mortality rate of the cancer and because many patients do not undergo operations, and therefore, we cannot obtain many samples of the cancerous tissue. What is more, until now there hasn't been much money available either to study this disease."

Explore further: Mayo Clinic reports new findings on noninvasive test for pancreatic cancer

More information: … ii/S0009898113000053

Related Stories

Mayo Clinic reports new findings on noninvasive test for pancreatic cancer

May 11, 2011
Pancreatic cancer has one of the highest mortality rates of any of the major cancers, and of the 43,000-plus Americans diagnosed with the disease each year, more than 94 percent die within five years of diagnosis. One reason ...

Scientists find gene that inhibits pancreas cancer spread

April 29, 2012
Scientists have identified a gene that slows the spread of pancreatic cancer tumours, paving the way for targeted treatment of one of the deadliest forms of the disease, said a paper published Sunday.

Study sheds light on how pancreatic cancer begins

November 29, 2012
A diagnosis of pancreatic cancer is particularly devastating since the prognosis for recovery is usually poor, with the cancer most often not detected until late stages.

Scientists discover link between inflammation, pancreatic cancer

April 11, 2011
Solving part of a medical mystery, researchers at the University of California, San Francisco have established a link between molecules found in an inflamed pancreas and the early formation of pancreatic cancer – a discovery ...

Diagnosis and management of pancreatic cancer: A review for physicians

April 22, 2013
Pancreatic cancer is the fourth leading cause of death from cancer, and while family physicians in Canada only see 1 cases a year, the number of cases is expected to increase as the population ages. A review in CMAJ (Canadian ...

Recommended for you

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.